AnaptysBio

ANAB · NASDAQ

$45.43−$3.81 (−7.74%)TodayMarket closed · Oct 20, 4:05 PM ET

Prev close $49.24

Latest news

Press releaseOct 19, 2:18 PM ETGlobe Newswire
Jemperli (dostarlimab) Approved in the U.S. as First and Only Immunotherapy for Adults with MSI-H/dMMR Locally Advanced Rectal Cancer
NewsSep 21, 5:06 PM ET
12 Health Care Stocks Moving In Monday's After-Market Session
Press releaseSep 21, 4:15 PM ETGlobe Newswire
Anaptys Announces Second Quarter and Transitional Fiscal Year 2026 Financial Results and Provides Business Update
Press releaseJul 15, 8:45 AM ETGlobe Newswire
A Weight-Loss Revolution Is Reshaping Bodies. This Preclinical Biotech Wants to Build What Comes Next
NewsJun 24, 8:03 AM ETAvi Kapoor
FedEx, Cerebras Systems And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
Press releaseMay 12, 4:15 PM ETGlobe Newswire
Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update
Press releaseApr 28, 7:12 PM ETPRNewswire
Vanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM Evidence
NewsApr 27, 1:55 PM ETVandana Singh
AnaptysBio Stock Rallies As Delaware Court Tosses Tesaro Breach Claim
Press releaseApr 24, 3:40 PM ETGlobe Newswire
Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro's Anticipatory Breach Claim
NewsApr 20, 1:05 PM ET
12 Health Care Stocks Moving In Monday's Intraday Session
Press releaseMar 27, 9:00 AM ETGlobe Newswire
First Tracks Biotherapeutics, the Planned Spin-Off of Anaptys, Secures Commitments of $145 Million in Private Placement
Press releaseMar 27, 9:00 AM ETGlobe Newswire
Anaptys Board of Directors Approves Spin-Off of First Tracks Biotherapeutics
Press releaseMar 27, 9:00 AM ETGlobe Newswire
Anaptys Announces $100 Million Stock Repurchase Plan and Provides a Business Update
NewsMar 3, 5:11 PM ET
CORRECTION: AnaptysBio Q4 EPS $1.58 Beats $0.80 Estimate, Sales $108.240M Beat $92.051M Estimate
Press releaseMar 3, 4:15 PM ETGlobe Newswire
Anaptys Provides Update on Business Separation and Announces Fourth Quarter and Full Year 2025 Financial Results
Press releaseFeb 25, 7:18 AM ETPRNewswire
Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis
NewsJan 9, 1:56 PM ETVandana Singh
AnaptysBio Pushes Back Against Lawsuit Over Cancer Drug Jemperli Royalties
Press releaseDec 15, 7:00 AM ETPRNewswire
Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis
NewsNov 21, 8:48 AM ETVandana Singh
GSK Unit Tesaro Sues AnaptysBio, Threatening Key Cancer Drug Jemperli Royalties
NewsNov 21, 8:16 AM ETAvi Kapoor
Elastic, Veeva Systems, HIVE Digital And Other Big Stocks Moving Lower In Friday's Pre-Market Session
NewsNov 21, 7:05 AM ET
12 Health Care Stocks Moving In Friday's Pre-Market Session
NewsAug 7, 9:02 AM ET
Analyst Expectations For AnaptysBio's Future
NewsJul 24, 2:00 PM ET
Analyst Expectations For AnaptysBio's Future
NewsJun 4, 1:16 PM ETAvi Kapoor
Crude Oil Falls Over 1%; ISM Services PMI Tumbles In May
Press releaseJun 3, 4:05 PM ETGlobe Newswire
Anaptys Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RA
NewsMay 28, 4:00 PM ET
Beyond The Numbers: 5 Analysts Discuss AnaptysBio Stock
NewsMay 6, 4:00 PM ET
Forecasting The Future: 6 Analyst Projections For AnaptysBio
Press releaseMay 5, 4:15 PM ETGlobe Newswire
Anaptys Announces First Quarter 2025 Financial Results and Provides Business Update
NewsMar 13, 8:08 AM ETAvi Kapoor
UiPath Posts Weak Revenue, Joins SentinelOne, American Eagle And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
NewsMar 13, 5:05 AM ETAvi Kapoor
Why Intel Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket
NewsMar 4, 7:00 AM ET
Where AnaptysBio Stands With Analysts
Press releaseFeb 27, 4:15 PM ETGlobe Newswire
Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
NewsFeb 4, 7:00 AM ET
Analyst Expectations For AnaptysBio's Future
Press releaseFeb 3, 7:30 AM ETPRNewswire
Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist
NewsJan 22, 4:58 AM ETAvi Kapoor
Why Netflix Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
NewsDec 18, 5:00 PM ET
Deep Dive Into AnaptysBio Stock: Analyst Perspectives (9 Ratings)
NewsDec 11, 4:06 PM ET
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
NewsDec 2, 1:01 PM ET
Key Takeaways From AnaptysBio Analyst Ratings
NewsOct 30, 12:31 PM ET
12 Health Care Stocks Moving In Wednesday's Intraday Session
NewsOct 30, 8:08 AM ET
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
NewsOct 30, 8:08 AM ET
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
NewsOct 21, 5:01 PM ET
A Glimpse Into The Expert Outlook On AnaptysBio Through 6 Analysts
NewsSep 30, 8:06 AM ET
12 Health Care Stocks Moving In Monday's Pre-Market Session

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Jemperli (dostarlimab) Approved in the U.S. as First and Only Immunotherapy for Adults with MSI-H/dMMR Locally Advanced Rectal Cancer

12 Health Care Stocks Moving In Monday's After-Market Session

Anaptys Announces Second Quarter and Transitional Fiscal Year 2026 Financial Results and Provides Business Update

A Weight-Loss Revolution Is Reshaping Bodies. This Preclinical Biotech Wants to Build What Comes Next

FedEx, Cerebras Systems And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session

Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update

Vanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM Evidence

AnaptysBio Stock Rallies As Delaware Court Tosses Tesaro Breach Claim

Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro's Anticipatory Breach Claim

12 Health Care Stocks Moving In Monday's Intraday Session

First Tracks Biotherapeutics, the Planned Spin-Off of Anaptys, Secures Commitments of $145 Million in Private Placement

Anaptys Board of Directors Approves Spin-Off of First Tracks Biotherapeutics

Anaptys Announces $100 Million Stock Repurchase Plan and Provides a Business Update

CORRECTION: AnaptysBio Q4 EPS $1.58 Beats $0.80 Estimate, Sales $108.240M Beat $92.051M Estimate

Anaptys Provides Update on Business Separation and Announces Fourth Quarter and Full Year 2025 Financial Results

Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis

AnaptysBio Pushes Back Against Lawsuit Over Cancer Drug Jemperli Royalties

Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis

GSK Unit Tesaro Sues AnaptysBio, Threatening Key Cancer Drug Jemperli Royalties

Elastic, Veeva Systems, HIVE Digital And Other Big Stocks Moving Lower In Friday's Pre-Market Session

12 Health Care Stocks Moving In Friday's Pre-Market Session

Analyst Expectations For AnaptysBio's Future

Analyst Expectations For AnaptysBio's Future

Crude Oil Falls Over 1%; ISM Services PMI Tumbles In May

Anaptys Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RA

Beyond The Numbers: 5 Analysts Discuss AnaptysBio Stock

Forecasting The Future: 6 Analyst Projections For AnaptysBio

Anaptys Announces First Quarter 2025 Financial Results and Provides Business Update

UiPath Posts Weak Revenue, Joins SentinelOne, American Eagle And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Why Intel Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket

Where AnaptysBio Stands With Analysts

Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Analyst Expectations For AnaptysBio's Future

Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist

Why Netflix Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket

Deep Dive Into AnaptysBio Stock: Analyst Perspectives (9 Ratings)

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Key Takeaways From AnaptysBio Analyst Ratings

12 Health Care Stocks Moving In Wednesday's Intraday Session

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

A Glimpse Into The Expert Outlook On AnaptysBio Through 6 Analysts

12 Health Care Stocks Moving In Monday's Pre-Market Session